Cinitapride: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 30: | Line 30: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:Cinitapride.svg|Cinitapride chemical structure | |||
File:3D_Cinitapride.png|3D model of Cinitapride | |||
File:Cinitapride_synthesis.svg|Cinitapride synthesis pathway | |||
</gallery> | |||
Latest revision as of 02:11, 18 February 2025
Cinitapride is a gastroprokinetic agent and antiulcer agent of the benzamide class which is marketed in Spain and Mexico. It acts as an agonist of the 5-HT1 and 5-HT4 receptors and as an antagonist of the 5-HT2 receptors.
Mechanism of action[edit]
Cinitapride has a dual mechanism of action. It works as an agonist of the 5-HT1 and 5-HT4 receptors, and as an antagonist of the 5-HT2 receptors. This dual action makes it effective in treating certain gastrointestinal conditions.
Uses[edit]
Cinitapride is used in the treatment of gastroesophageal reflux disease (GERD), non-ulcer dyspepsia, and as a prokinetic agent in conditions such as gastroparesis and functional dyspepsia.
Side effects[edit]
The most common side effects of cinitapride include dizziness, headache, diarrhea, and abdominal pain. In rare cases, it can cause extrapyramidal symptoms.
Contraindications[edit]
Cinitapride is contraindicated in patients with known hypersensitivity to the drug, and in those with gastrointestinal hemorrhage, mechanical obstruction, or perforation.
Interactions[edit]
Cinitapride may interact with other drugs such as anticholinergic medications, antipsychotic drugs, and antiarrhythmic drugs.
Pharmacokinetics[edit]
Cinitapride is rapidly absorbed from the gastrointestinal tract and undergoes extensive first-pass metabolism in the liver. It is excreted primarily in the urine.


